1. Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer
   Seyer Safi et al, 2017, OncoImmunology CrossRef
2. PRODUCTION OF PURIFIED HUMAN RECOMBINANT ANTIGEN PRAME AND SPECIFIC MONOCLONAL ANTIBODIES
   Yu. P. Finashutina et al, 2015, Russian Journal of Biotherapy CrossRef
3. Identification of the Relationships between Tumor Mutation Burden with Immune Infiltrates in Liver Hepatocellular Carcinoma
   家麟 曲, 2021, Advances in Clinical Medicine CrossRef
4. In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer
   Anke Vanderstraeten et al, 2016, International Journal of Molecular Sciences CrossRef
5. Common and distinct features of potentially predictive biomarkers in small cell lung carcinoma and large cell neuroendocrine carcinoma of the lung by systematic and integrated analysis
   Shenghua Dong et al, 2020, Molecular Genetics & Genomic Medicine CrossRef
6. Cancer testis antigen PRAME: An anti‐cancer target with immunomodulatory potential
   Adviti Naik et al, 2021, Journal of Cellular and Molecular Medicine CrossRef
7. New Approaches in Immunotherapy
   David F. Heigener et al, 2015, New Therapeutic Strategies in Lung Cancers CrossRef
8. Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
   John S. Yi et al, 2017, Clinical Cancer Research CrossRef
9. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor–Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma
   Kathryn J. Brayer et al, 2016, Cancer Discovery CrossRef
10. Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer
    Florian Augustin et al, 2015, Journal of Clinical Pathology CrossRef
11. Theory and Practice of Immunotherapy Directed against the PRAME Antigen
    V.A. Misyurin, 2018, Clinical oncohematology CrossRef
12. Immunotherapy and lung cancer: current developments and novel targeted therapies
    Duarte Domingues et al, 2014, Immunotherapy CrossRef
13. Immune responses against shared antigens are common in esophago-gastric cancer and can be enhanced using CD40-activated B cells
    Martin Thelen et al, 2022, Journal for ImmunoTherapy of Cancer CrossRef
14. The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer
    Yichi Xu et al, 2020, Cell Proliferation CrossRef
15. MAGE-A expression, immune microenvironment, and prognosis in upper urinary tract carcinoma
    Naohiro Makise et al, 2016, Human Pathology CrossRef
16. Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3LL tumor cells to mediate MDSC chemoattraction via Fas signaling
    Fei Yang et al, 2015, Cellular & Molecular Immunology CrossRef
17. Preferentially Expressed Antigen in Melanoma Is a Multifaceted Cancer Testis Antigen with Diverse Roles as a Biomarker and Therapeutic Target
    Mukulika Bose, 2023, International Journal of Translational Medicine CrossRef
18. Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
    Caroline Tosch et al, 2017, Journal for ImmunoTherapy of Cancer CrossRef